Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors.
暂无分享,去创建一个
[1] J. Schlom,et al. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. , 1997, Vaccine.
[2] J. Yewdell,et al. MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. , 1997, Journal of immunology.
[3] S. Rosenberg. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. , 1996, Journal of the National Cancer Institute.
[4] A. García-Sastre,et al. Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. , 1996, Cellular immunology.
[5] B. Moss,et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. , 1996, Journal of immunology.
[6] H. Pircher,et al. On T Cell Memory: Arguments for Antigen Dependence , 1996, Immunological reviews.
[7] S. Rosenberg,et al. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. , 1996, Journal of immunology.
[8] P. Borrow,et al. Discriminated selection among viral peptides with the appropriate anchor residues: implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection , 1995, Journal of virology.
[9] P. Coulie,et al. From defined human tumor antigens to effective immunization? , 1995, Immunology today.
[10] S. Rosenberg,et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. , 1995, Journal of immunology.
[11] S. Rosenberg,et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. , 1995, Journal of immunology.
[12] J. Lippolis,et al. virus 40 T antigen . cytotoxic T-lymphocyte epitopes within simian Hierarchy among multiple H-2 b-restricted , 1995 .
[13] D. Fuller,et al. Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. , 1995, Vaccine.
[14] H. von Boehmer,et al. On the cellular basis of immunological T cell memory. , 1995, Immunity.
[15] D. Fuller,et al. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. , 1994, AIDS research and human retroviruses.
[16] M. Skinner,et al. Deletion of fowlpox virus homologues of vaccinia virus genes between the 3 beta-hydroxysteroid dehydrogenase (A44L) and DNA ligase (A50R) genes. , 1994, The Journal of general virology.
[17] J. Schlom,et al. Immune response to a carcinoembryonic antigen polynucleotide vaccine. , 1994, Cancer research.
[18] R M Zinkernagel,et al. Impairment and delay of neutralizing antiviral antibody responses by virus-specific cytotoxic T cells. , 1993, Journal of immunology.
[19] J. Ulmer,et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.
[20] J. Yewdell,et al. Identification of human cancers deficient in antigen processing , 1993, The Journal of experimental medicine.
[21] R. Zinkernagel,et al. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. , 1993, Vaccine.
[22] D. Montefiori,et al. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. , 1992, The Journal of infectious diseases.
[23] J. Schlom,et al. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. , 1992, Journal of the National Cancer Institute.
[24] P. Greenberg,et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein , 1991, The Lancet.
[25] S. Goebel,et al. Nucleotide sequence analysis of a 10.5 kbp HindIII fragment of fowlpox virus: relatedness to the central portion of the vaccinia virus HindIII D region. , 1990, The Journal of general virology.
[26] G. Acsadi,et al. Direct gene transfer into mouse muscle in vivo. , 1990, Science.
[27] D. Gray,et al. T cell memory is short-lived in the absence of antigen , 1988, Nature.
[28] J. Brown,et al. Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. , 1988, Proceedings of the National Academy of Sciences of the United States of America.